Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Apellis Pharmaceuticals Inc shares valued at $122,450 were purchased by Watson David O. on Dec 16 ’25. At $24.49 per share, Watson David O. acquired 5,000 shares.
Also, Watson David O. sold 5,000 shares, netting a total of over 100,300 in proceeds. Following the sale of shares at $20.06 each, the insider now holds 108,730 shares.
Before that, Watson David O. had added 5,000 shares to its account. In a trade valued at $100,300, the Officer bought Apellis Pharmaceuticals Inc shares for $20.06 each.
As published in their initiating research note from Wolfe Research on November 06, 2025, Apellis Pharmaceuticals Inc [APLS] has been a Peer perform. Analysts at Wells Fargo started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid October. As of September 26, 2025, Goldman has decreased its “Neutral” rating to a “Sell” for APLS. Earlier on May 09, 2025, Raymond James downgraded its rating. Their new recommendation was “an Outperform” for APLS stock which previously was a “a Strong buy”.
Analyzing APLS Stock Performance
On last trading session, Apellis Pharmaceuticals Inc [NASDAQ: APLS] plunged -0.43% to $25.2. The stock’s lowest price that day was $25.0199, but it reached a high of $25.95 in the same session. During the last five days, there has been a surge of approximately 2.11%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -24.07%. Shares of the company reached a 52-week high of $35.57 on 01/07/25 and a 52-week low of $16.10 on 05/15/25.
Support And Resistance Levels for Apellis Pharmaceuticals Inc (APLS)
According to the 24-hour chart, there is a support level at 24.83, which, if violated, would cause prices to drop to 24.46. In the upper region, resistance lies at 25.76. The next price resistance is at 26.32. RSI (Relative Strength Index) is 65.18 on the 14-day chart, showing neutral technical sentiment.
Is Apellis Pharmaceuticals Inc subject to short interest?
Stocks of Apellis Pharmaceuticals Inc saw a sharp rise in short interest on 2025-11-28 jumping by 0.88 million shares to 16.1 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 15.21 million shares. A jump of 5.49% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.21 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.21.
Which companies own the most shares of Apellis Pharmaceuticals Inc (APLS)?
In terms of Apellis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 27 in the next 12 months, up nearly 6.68% from the previous closing price of $25.31. Analysts anticipate Apellis Pharmaceuticals Inc stock to reach 52 by 2025, with the lowest price target being 18. In spite of this, 14 analysts ranked Apellis Pharmaceuticals Inc stock as Buy at the end of 2025. On May 09, 2025, BofA Securities assigned a price target of “a Neutral” to the stock and downgraded coverage with a $23.
